This PLOS ONE paper, co-authored by Alban Bessède, CSO of Explicyte, demonstrates that the expression of tryptophan-degrading enzyme IDO1 is not strictly associated with L-Kynurenine production in breast and colorectal cancer tissues. The study suggests that the in situ detection of L-Kynurenine could serve to stratify patients in the context of cancer immunotherapies targeting tryptophan catabolic enzymes: indoleamine 2,3-dioxygenase (IDO-1/-2) or tryptophan 2,3-dioxygenase 2 (TDO2).

Access the article

Leave a Reply

Your email address will not be published.

This field is required.

You may use these <abbr title="HyperText Markup Language">html</abbr> tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>

This field is required.

WordPress Lightbox